Vaccines, Blood & Biologics

Division of Inspections and Surveillance (DIS)

The Division of Inspections and Surveillance (DIS) within OCBQ has many responsibilities, including the following:

Inspection, Surveillance, and Compliance Activities

  • Coordinates and provides support and direction to district offices for investigations and surveillance inspections. Supports the CBER pre-approval inspection program.
  • Works with the Office of Regulatory Affairs (ORA) to prepare inspection work plans and allocate resources for the CBER inspection programs.
  • Develops and updates CBER compliance programs, coordinates and directs their implementation, and advises other Agency components on these programs.
  • Plans and directs investigation and surveillance assignments in response to reports regarding product defects, adverse events, complaints, biological product deviation reports, and allegations of violative activity. Evaluates the related inspection and investigation reports.
  • Directs CBER’s Bioresearch Monitoring program with oversight of clinical investigators, institutional review boards, and sponsors of clinical research for biological products. Plans and directs inspection assignments, evaluates Establishment Inspection Reports, and takes appropriate compliance actions, in coordination with other Agency components, including Untitled Letters, Warning Letters, and the initiation of disqualification of clinical investigators.

Biological Product Deviation Reports (BPDRs) and Blood Collection and Transfusion Related Fatality Reports

  • Directs CBER’s program for biological product deviation reports (including HCT/P deviation reports and medical device reports), and reports of complications of blood collection or transfusion confirmed to be fatal. Coordinates case reviews, as appropriate, by a committee of medical officers.

Additional Information about DIS

Additional information about the responsibilities of DIS is available in FDA’s Staff Manual Guide.

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 03/29/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English